TWEAK and the progression of renal disease: Clinical translation

Nephrology Dialysis Transplantation

Volumn 29, Issue SUPPL. 1, 2014, Pages

  Sanz, Ana B ^a,b   Izquierdo, M Concepcion ^a,b   Sanchez Niño, Maria Dolores ^b,c   Ucero, Alvaro C ^a,b   Egido, Jesus ^a,d,e   Ruiz Ortega, Marta ^a,b,d   Ramos, Adrián Mario ^a,b   Putterman, Chaim ^f   Ortiz, Alberto ^a,b,d,e  

^a UAM)   (Spain)

^b REDINREN   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^e IRSIN   (Spain)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

apoptosis; clinical trials; fibrosis; inflammation; necroptosis; proteinuria

Indexed keywords

ANTIBODY; BIIB 023; ENAVATUZUMAB; FIBROBLAST GROWTH FACTOR INDUCIBLE 14; PROTEIN TWEAK; RECEPTOR; RO 5458640; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADVANCED CANCER; AGING; ARTICLE; CLINICAL PRACTICE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; GLOMERULONEPHRITIS; HUMAN; IMMUNE RESPONSE; IN VIVO STUDY; INFLAMMATORY CELL; KIDNEY CELL CULTURE; KIDNEY DEVELOPMENT; KIDNEY DISEASE; KIDNEY INJURY; KIDNEY TUBULE CELL; LETHALITY; LUPUS ERYTHEMATOSUS NEPHRITIS; MESANGIUM CELL; MITOGENESIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PODOCYTE; PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SOLID TUMOR;

APOPTOSIS; CLINICAL TRIALS; FIBROSIS; INFLAMMATION; NECROPTOSIS; PROTEINURIA;

ANIMALS; APOPTOSIS; DISEASE PROGRESSION; HUMANS; KIDNEY DISEASES; MICE; TRANSLATIONAL MEDICAL RESEARCH; TUMOR NECROSIS FACTORS;

EID: 84893852470     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft342     Document Type: Review

References (76)

1. Sanz AB, Sanchez-Niño MD, Ortiz A. TWEAK, a multifunctional cytokine in kidney injury. Kidney Int 2011; 80: 708-718
2. Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: Discovery, biology and therapeutic targeting. Nat Rev Drug Discov 2008; 7: 411-425
3. Dohi T, Burkly LC. The TWEAK/Fn14 pathway as an aggravating and perpetuating factor in inflammatory diseases: Focus on inflammatory bowel diseases. J Leukoc Biol 2012; 92: 265-279
4. Burkly LC, Michaelson JS, Zheng TS. TWEAK/Fn14 pathway: An immunological switch for shaping tissue responses. Immunol Rev 2011; 244: 99-114
5. Chicheportiche Y, Bourdon PR, Xu H et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 1997; 272: 32401-32410
6. Brown SA, Ghosh A, Winkles JA. Full-length, membrane-Anchored TWEAK can function as a juxtacrine signaling molecule and activate the NF-kappaB pathway. J Biol Chem 2010; 285: 17432-17441
7. Marsters SA, Sheridan JP, Pitti RM et al. Identification of a ligand for the death-domain-containing receptor Apo3. Curr Biol 1998; 8: 525-528
8. Baxter FO, Came PJ, Abell K et al. IKKbeta/2 induces TWEAK and apoptosis in mammary epithelial cells. Development 2006; 133: 3485-3494
9. Nakayama M, Kayagaki N, Yamaguchi N et al. Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity. J Exp Med 2000; 192: 1373-1380
10. Kaplan MJ, Lewis EE, Shelden EA et al. The apoptotic ligands TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells. J Immunol 2002; 169: 6020-6029
11. Kim SH, Kang YJ, Kim WJ et al. TWEAK can induce proinflammatory cytokines and matrix metalloproteinase-9 in macrophages. Circ J 2004; 68: 396-399
12. Roos C, Wicovsky A, Müller N et al. Soluble and transmembrane TNFlike weak inducer of apoptosis differentially activate the classical and noncanonical NF-kappa B pathway. J Immunol 2010; 185: 1593-1605
13. Meighan-Mantha RL, Hsu DK, Guo Y et al. The mitogen-inducible Fn14 gene encodes a type I transmembrane protein that modulates fibroblast adhesion and migration. J Biol Chem 1999; 274: 33166-33176
14. Brown SA, Hanscom HN, Vu H et al. TWEAK Binding to the Fn14 cysteine- rich domain depends on charged residues located in both the A1 and D2 modules. Biochem J 2006; 397: 297-304
15. He F, Dang W, Saito K et al. Solution structure of the cysteine-rich domain in Fn14, a member of the tumor necrosis factor receptor superfamily. Protein Sci 2009; 18: 650-656
16. Brown SA, Richards CM, Hanscom HN et al. The Fn14 cytoplasmic tail binds tumour-necrosis-factor-receptor-Associated factors 1, 2, 3 and 5 and mediates nuclear factor-kappaB activation. Biochem J 2003; 371(Pt 2): 395-403
17. Bover LC, Cardó-Vila M, Kuniyasu A et al. A previously unrecognized protein-protein interaction between TWEAK and CD163: Potential biological implications. J Immunol 2007; 178: 8183-8194
18. Moreno JA, Muñoz-García B, Martín-Ventura JL et al. The CD163-expressing macrophages recognize and internalize TWEAK: Potential consequences in atherosclerosis. Atherosclerosis 2009; 207: 103-110
19. Burkly LC, Michaelson JS, Hahm K et al. TWEAKing tissue remodeling by a multifunctional cytokine: Role of TWEAK/Fn14 pathway in health and disease. Cytokine 2007; 40: 1-16
20. Justo P, Sanz AB, Sanchez-Niño MD et al. Cytokine cooperation in renal tubular cell injury: The role of TWEAK. Kidney Int 2006; 70: 1750-1758
21. Gao HX, Campbell SR, Burkly LC et al. TNF-like weak inducer of apoptosis (TWEAK) induces inflammatory and proliferative effects in human kidney cells. Cytokine 2009; 46: 24-35
22. Molano A, Lakhani P, Aran A et al. TWEAK Stimulation of kidney resident cells in the pathogenesis of graft versus host induced lupus nephritis. Immunol Lett 2009; 125: 119-128
23. Martín Cleary C, Moreno JA, Fernandez B et al. Glomerular haematuria, renal interstitial haemorrhage and acute kidney injury. Nephrol Dial Transplant 2010; 25: 4103-4106
24. Saitoh T, Nakayama M, Nakano H et al. TWEAK Induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation. J Biol Chem 2003; 278: 36005-36012
25. Tran NL, McDonough WS, Savitch BA et al. The tumor necrosis factorlike weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFkappaB pathway activation and BCL-XL/BCL-W expression. J Biol Chem 2005; 280: 3483-3492
26. Mittal A, Bhatnagar S, Kumar A et al. The TWEAK-Fn14 system is a critical regulator of denervation-induced skeletal muscle atrophy in mice. J Cell Biol 2010; 188: 833-849
27. Tirnitz-Parker JE, Viebahn CS, Jakubowski A et al. Tumor necrosis factorlike weak inducer of apoptosis is a mitogen for liver progenitor cells. Hepatology 2010; 52: 291-302
28. Haile WB, Echeverry R, Wu J et al. The interaction between tumor necrosis factor-like weak inducer of apoptosis and its receptor fibroblast growth factor-inducible 14 promotes the recruitment of neutrophils into the ischemic brain. J Cereb Blood Flow Metab 2010; 30: 1147-1156
29. Ucero AC, Berzal S, Ocaña-Salceda C et al. A polymeric nanomedicine diminishes inflammatory events in renal tubular cells. PLoS One 2013; 8: E51992
30. Sanz AB, Justo P, Sanchez-Niño MD et al. The cytokine TWEAK modulates renal tubulointerstitial inflammation. J Am Soc Nephrol 2008; 19: 695-703
31. Sanz AB, Sanchez-Niño MD, Izquierdo MC et al. Tweak induces proliferation in renal tubular epithelium: A role in uninephrectomy induced renal hyperplasia. J Cell Mol Med 2009; 13(9B): 3329-3342
32. Sanz AB, Sanchez-Niño MD, Izquierdo MC et al. TWEAK Activates the non-canonical NFkappaB pathway in murine renal tubular cells: Modulation of CCL21. PLoS One 2010; 5: E8955
33. Izquierdo MC, Sanz AB, Mezzano S et al. TWEAK (tumor necrosis factorlike weak inducer of apoptosis) activates CXCL16 expression during renal tubulointerstitial inflammation. Kidney Int 2012; 81: 1098-1107
34. Moreno JA, Izquierdo MC, Sanchez-Ni?o MD et al. The inflammatory cytokines TWEAK and TNFα reduce renal klotho expression through NFκB. J Am Soc Nephrol 2011; 22: 1315-1325
35. Ortiz A, Lorz C, Catalán MP et al. Expression of apoptosis regulatory proteins in tubular epithelium stressed in culture or following acute renal failure. Kidney Int 2000; 57: 969-981
36. Linkermann A, De Zen F, Weinberg J et al. Programmed necrosis in acute kidney injury. Nephrol Dial Transplant 2012; 27: 3412-3419
37. Campbell S, Burkly LC, Gao HX et al. Proinflammatory effects of TWEAK/Fn14 interactions in glomerular mesangial cells. J Immunol 2006; 176: 1889-1898
38. Maecker H, Varfolomeev E, Kischkel F et al. TWEAK attenuates the transition from innate to adaptive immunity. Cell 2005; 123: 931-944
39. Park JS, Park MK, Lee SY et al. TWEAK Promotes the production of interleukin- 17 in rheumatoid arthritis. Cytokine 2012; 60: 143-149
40. van Kuijk AW, Wijbrandts CA, Vinkenoog Met al. TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid arthritis compared to psoriatic arthritis and its response to tumour necrosis factor blockade. Ann Rheum Dis 2010; 69: 301-304
41. Muñoz-García B, Martín-Ventura JL, Martínez E et al. Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: Modulation by atorvastatin. Stroke 2006; 37: 2044-2053
42. Desplat-Jégo S, Feuillet L, Creidy R et al. TWEAK Is expressed at the cell surface of monocytes during multiple sclerosis. J Leukoc Biol 2009; 85: 132-135
43. Lichtner M, Marañón C, Vidalain PO et al. HIV Type 1-infected dendritic cells induce apoptotic death in infected and uninfected primary CD4 T lymphocytes. AIDS Res Hum Retroviruses 2004; 20: 175-182
44. Son A, Oshio T, Kawamura YI et al. TWEAK/Fn14 pathway promotes a T helper 2-type chronic colitis with fibrosis in mice. Mucosal Immunol 2013; March 6. doi: 10.1038/mi.2013.10. [Epub ahead of print] PMID:23462911
45. Sun J, Langer WJ, Devish K et al. Compensatory kidney growth in estrogen receptor-Alpha null mice. Am J Physiol Renal Physiol 2006; 290: F319-F323
46. Flyvbjerg A, Bennett WF, Rasch R et al. Compensatory renal growth in uninephrectomized adult mice is growth hormone dependent. Kidney Int 1999; 56: 2048-2054
47. Jakubowski A, Ambrose C, Parr M et al. TWEAK induces liver progenitor cell proliferation. J Clin Invest 2005; 115: 2330-2340
48. Girgenrath M, Weng S, Kostek CA et al. TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration. EMBO J 2006; 25: 5826-5839
49. Hotta K, Sho M, Yamato I et al. Direct targeting of fibroblast growth factor-inducible 14 protein protects against renal ischemia reperfusion injury. Kidney Int 2011; 79: 179-188
50. Muñoz-García B, Moreno JA, López-Franco O et al. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) enhances vascular and renal damage induced by hyperlipidemic diet in ApoE-knockout mice. Arterioscler Thromb Vasc Biol 2009; 29: 2061-2068
51. Ucero AC, Benito-Martin A, Fuentes-Calvo I et al. TNF-related weak inducer of apoptosis (TWEAK) promotes kidney fibrosis and Ras-dependent proliferation of cultured renal fibroblast. Biochim Biophys Acta 2013; 1832: 1744-1755
52. Lu J, Kwan BC, Lai FM et al. Gene expression of TWEAK/Fn14 and IP-10/ CXCR3 in glomerulus and tubulointerstitium of patients with lupus nephritis. Nephrology (Carlton) 2011; 16: 426-432
53. Lu J, Szeto CC, Tam LS et al. Relationship of intrarenal gene expression and the histological class of lupus nephritis-A study on repeat renal biopsy. J Rheumatol 2012; 39: 1942-1947
54. Zhi-Chun L, Qiao-Ling Z, Zhi-Qin L et al. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) mediates p38 mitogen-Activated protein kinase activation and signal transduction in peripheral blood mononuclear cells from patients with lupus nephritis. Inflammation 2012; 35: 935-943
55. Wang C, Chen LL, Pan HF et al. Expression of human tumor necrosis factor-like weak inducer of apoptosis in patients with systemic lupus erythematosus. Clin Rheumatol 2012; 31: 335-339
56. Schwartz N, Rubinstein T, Burkly LC et al. Urinary TWEAK as a biomarker of lupus nephritis: A multicenter cohort study. Arthritis Res Ther 2009; 11: R143
57. Schwartz N, Su L, Burkly LC et al. Urinary TWEAK and the activity of lupus nephritis. J Autoimmun 2006; 27: 242-250
58. El-Shehaby A, Darweesh H, El-KhatibM et al. Correlations of urinary biomarkers, TNF-like weak inducer of apoptosis (TWEAK), osteoprotegerin (OPG), monocyte chemoattractant protein-1 (MCP-1), and IL-8 with lupus nephritis. J Clin Immunol 2011; 31: 848-856
59. Xuejing Z, Jiazhen T, Jun L et al. Urinary TWEAK level as a marker of lupus nephritis activity in 46 cases. J Biomed Biotechnol 2012; 2012: 359647
60. Zhao Z, Burkly LC, Campbell S et al. TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versushost model of systemic lupus erythematosus. J Immunol. 2007; 179: 7949-7958
61. Xia Y, Campbell SR, Broder A et al. Inhibition of the TWEAK/Fn14 pathway attenuates renal disease in nephrotoxic serum nephritis. Clin Immunol 2012; 145: 108-121
62. Izquierdo MC, Perez-Gomez MV, Sanchez-Niño MD et al. Klotho, phosphate and inflammation/ageing in chronic kidney disease. Nephrol Dial Transplant 2012; 27 (Suppl. 4): Iv6-i10
63. Elewa U, Sanchez-Niño MD, Martin-Cleary C et al. Cardiovascular risk biomarkers in CKD: The inflammation link and the road less traveled. Int Urol Nephrol 2012; 44: 1731-1744
64. Ortiz A, Massy ZA, Fliser D et al. Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis. Nat Rev Nephrol 2012; 8: 141-150
65. Carrero JJ, Ortiz A, Qureshi AR et al. Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. Clin J Am Soc Nephrol 2009; 4: 110-118
66. Kuro-o M, Matsumura Y, Aizawa H et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390: 45-51
67. Kurosu H, Yamamoto M, Clark JD et al. Suppression of aging in mice by the hormone Klotho. Science 2005; 309: 1829-1833
68. Izquierdo MC, Sanz AB, Sánchez-Niño MD et al. Acute kidney injury transcriptomics unveils a relationship between inflammation and ageing. Nefrologia 2012; 32: 715-723
69. http://clinicaltrials.gov/ct2/show/NCT00771329 (5 May 2013, date last accessed
70. http://clinicaltrials.gov/ct2/show/NCT01499355 (14 April 2013, date last accessed
71. Sanz AB, Sanchez-Niño MD, Carrasco S et al. Inflammatory cytokines and survival factors from serum modulate tweak-induced apoptosis in PC-3 prostate cancer cells. PLoS One 2012; 7: E47440
72. Michaelson JS, Amatucci A, Kelly R et al. Development of an Fn14 agonistic antibody as an anti-tumor agent. MAbs 2011; 3: 362-375
73. Culp PA, Choi D, Zhang Y et al. Antibodies to TWEAK receptor inhibit human tumor growth through dual mechanisms. Clin Cancer Res 2010; 16: 497-508
74. http://clinicaltrials.gov/ct2/show/NCT00738764 (5 May 2013, date last accessed
75. http://clinicaltrials.gov/ct2/show/NCT01383733 (5 May 2013, date last accessed
76. Santamaría B, Benito-Martin A, Ucero AC et al. A nanoconjugate Apaf-1 inhibitor protects mesothelial cells from cytokine-induced injury. PLoS One 2009; 4: E6634